TargetBeta
ALDH7A1
aldehyde dehydrogenase 7 family member A1 · also EPD, PDE, ATQ1 · Aldehyde dehydrogenases
2 programs in company-led studies act on ALDH7A1, from 2 companies: 1 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| Roflumilastrule | AstraZeneca | inhibitor | phase 4 | 613 running | PDE4A, PDE4B, PDE4C, PDE4D | NCIt |
| ensifentrinerule | Merck | inhibitor | phase 3 | 172 running | PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D | NCIt |
Conditions their studies are in
- Asthma, 2 programs
- Pulmonary Disease, Chronic Obstructive, 2 programs
- Cystic Fibrosis, 1 program
- Dermatitis, Atopic, 1 program
- Diabetes Mellitus, Type 2, 1 program
- Psoriasis, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 1, 2027ensifentrine · Merck · phase 3 · NCT05270525
- Jun 30, 2027Roflumilast · AstraZeneca · phase 4 · NCT07683806
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.